Jenburkt Pharmaceuticals has been awarded an NSIC-CRISIL rating of -- NSIC-CRISIL SE-1A. The rating indicates highest performance capability and high financial strength and it is valid till June 29, 2012. The company has been rated under the same category for the fourth year in continuation.
Recently, the company was bestowed with ‘National Award for Excellence in Cost Management-2010’ as the first awardee under the category of the ‘Private Manufacturing-(small)’ by the Institute of Cost and Works Accountants of India (ICWAI), which is a statutory body under an act of parliament, at the 8th national award function held at Vigyan Bhawan, New Delhi, on July 18, 2011.
Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: